February 9, 2012 X. Wu and coworkers show importance of NOX4 in insulin resistance Wu and coworkers undertook characterization of pathway-selective insulin resistance and responsivenes in liver and hepatocytes by examining targets of the insulin receptor including NOX4 pathways. They comcluded that functional disturbance of a single molecule, NAD(P)H oxidase 4, is sufficient to induce the key harmful features of deranged insulin signaling in type 2 diabetes mellitus, obesity, and other conditions associated with hyperinsulinemia and pathway-selective insulin resistance and responsiveness. Ref: Wu, X., et al (2012) Arterioscler Thromb Vasc Biol. 2012 Feb 9. (Epubl ahead of print) --------------------------------------------------------------------------------------------------------------------------------------------- November 20, 2011 New publication from Glucox Biotech and academic partners The mission of Glucox Botech is to identify compounds that improve glucose homeostasis. Together with two acadmic groups at Karolinska Institutet and Stockholm University, Glucox Biotech has shown that shikonin, a naphthoquinone derived from the Cinese plant Lithospermum erythrorhizon, increases glucose uptake i skeletal muscle cells. Shikonin increases uptake via an insulin-independent, calcium dependent, pathway. The beneficial effects of shikonin on glucose metabolism, both in vitro and in vivo, show that the compound possesses properties that make it of considerable interest for developing novel treatments of type 2 diabetes. Ref: Öberg, A.I., et al (2011) PLoS One, 6 (7): e22510 --------------------------------------------------------------------------------------------------------------------------------------------- October 3, 2011 Agreement with Redoxis AB Glucox Biotech has signed an agreement with Redoxis AB for the further development of Glucox´ lead compound for the treatment of type 2 diabetes and complications. On the basis of promising results from ADME and selectivity caracterizations of a selected number of compounds efficiently inhibiting NOX4, a lead compound an a backup has been nominated. According to the agreement, Redoxis AB undertakes, on a fee-for-service basis, to determine the pharmacokinetics of the lead compound and performe a first preliminary toxicity study to pinpoint doses for the planed preclinical efficacy studies. --------------------------------------------------------------------------------------------------------------------------------------------- March 14, 2011 Agreement with Department of Pharmacy, Uppsala University Glucox Biotech annnounces the signing of an agreement with Department of Pharmacy, Uppsala University for the further characterization of Glucox' small molecule inhibitors of NOX4. Glucox' R&D has resulted in a set of promising NOX4 inhibitor compounds that presently are in a hit-to-lead phase. The commissioned activities will be carried out with the Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP). According to the agreement UDOPP will help Glucox to optimize the compound development project and deliver high quality data as a basis for selection of candidate drugs through applications of its research tools. In return Glucox will provide financial support for a part time post-doctorial researcher with the Department of Pharmacy. --------------------------------------------------------------------------------------------------------------------------------------------- December 22, 2010 Agreement with Redoxis AB Glucox Biotech announceed today the signing of a contract with Redoxis AB for further studie on Glucox smal molecule NOX4 inhibitors. Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase. Redoxis AB is a research company with focused research on autoimmune diseases and with a recognized competence in R&D related to NAD(P)H-oxidase based disease mechanisms. According to the contract Redoxis undertakes to, on a fee-for-service basis, further study the influence of Glucox´ small molecule NOX4 inhibitors on NAD(P)H-oxidase. --------------------------------------------------------------------------------------------------------------------------------------------- August 29, 2010 Change of CEO and Chair Erik Walum, former Chair of the Board of Directors was today appointed new CEO of Glucox Biotech AB. Mona Wilcke, co-founder of Glucox Biotech and former CEO, was at the same time appointed new Chair of the Board of Directors.Erik Walum (PhD) is a former professor of Neurotoxicology at Stockholm University and has served as Head of Molecular Biology and Genomics at Pharmacia and Head of Obesity Pharmacology at Biovitrum. He became member of the Board in 2006 and Chair of the board in 2008. Mona Wilcke (PhD) has a broad experience in business development as well as research in the metabolic and diabetes field. She has been working at several biotech and large pharmaceutical companies, among them Pharmacia. Besides being Chair of the Board of Directors she will also serves as CSO. Mona Wilcke has been a member of the Board since the start of the company in 2004. --------------------------------------------------------------------------------------------------------------------------------------------- April 29, 2010 Approval of patent in Europe Glucox Biotech has been approved its third patent application in Europe in April 2010. The examining Division has granted the European patent that will cover the use of NAD(P)H oxidase inhibitors as a medicament in the treatment and/or prevention of diseases caused by diabetes. The patent received will provide a strong commercial protection for pharmaceutical products proceeding within the company and adds extended value to the existing IP-portfolio of Glucox Biotech. Glucox Biotech is currently testing its novel compounds in animal tests and is preparing for a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance as well as diabetes complications. --------------------------------------------------------------------------------------------------------------------------------------------- April 15, 2010 Initiation of aminal studie case for novel compounds Glucox Biotech has initiated a comprehensive animal study to confirm a proof-of-concept with the selected compounds of interest based on the screening compound from the potential hit series that resulted in few very promising chemical series amenable for lead generation. |  Press release 15 May 2007 Promising Results in Treatment with GLX ----------------- Press release 29 December 2006 US Patent Received for Diabetes Treatment ----------------- Press release 28 September 2006 Glucox' Unique Research Discovery Confirmed by US Scientist Press release 10 July 2006 Patent Application Submitted for the GLX Compounds Press release 5 June 2006 A Significant Preclinical Milestone Achieved Press release 7 February 2006 Positive Results from the First Time In Animal Study Press release 10 January 2006 Changes in Board of Directors Press release 10 November 2005 Evaluation and Selection of Glucox Biotech' Lead Drug Candidates Press release 15 December 2004 First Milestone Succeeded. |
News |